Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date *

Nanoparticle-Based Drug Delivery System: A Patient-Friendly Chemotherapy for Oncology

“…54,55 Liposomes are the most widely used NPs, and they exhibit quite effective capabilities in the following areas: (1) increase the solubility of hydrophobic drugs; (2) improve the biological distribution of chemotherapeutic drugs and the selectivity of therapeutic agents; (3) reduce the cytotoxicity of chemotherapeutic drugs to normal tissues, thereby reducing its toxic side effects; and (4) extend the cycle time of chemotherapeutic drugs and control the release. 56 -59 In the past few years, many liposome chemotherapeutic agents have observed positive results in the clinic, and some of them have been approved by the European Medicines Agency and the US Food and Drug Administration (FDA) for the treatment of various Kind of cancer. Table 1 lists some of the liposome chemotherapeutic agents approved by the FDA, and there are a variety of anticancer drug-encapsulated liposome preparations at different stages of clinical trials or waiting for approval, as shown in Table 2.…”

Polymeric nanoparticle vaccines to combat emerging and pandemic threats

“…Learning the lesson from the lipid-based delivery vehicles like Doxil® approved by the US FDA for human use [ 227 ], there have been considerable efforts to develop lipid coated polymeric particles for vaccine applications. A variety of polymer structures has been coated with lipid components, including predominantly solid-core polymeric particles having sizes ranging from micro-to nanometer [ 65 , 80 , 140 , 148 , 228 , 229 ], and, to a lesser extent, hollow-core polymeric nanoparticles [ 96 ] and polymersomes [ 230 ].…”

Tumor grafted – chick chorioallantoic membrane as an alternative model for biological cancer research and conventional/nanomaterial-based theranostics evaluation

“…The increasing number of novel platforms aiming to improve cancer diagnosis and therapy intensifies the demand for qualified preclinical tumor models. Nanomaterial (NM)-based imaging and treatment systems are among the leading innovative technologies, which gained further considerations following the approval for clinical use of Caelyx ® (doxorubicin liposomal formulation; also known as Doxil ® in the US), Abraxane ® (albumin-bound paclitaxel approved for breast cancer, nonsmall cell lung cancer, and pancreatic cancer), Onivyde ® (liposomal formulation of irinotecan for pancreatic cancer), and other nanoformulations of known approved anticancer agents [122]. Nowadays, nanoparticles (NPs) are mainly developed to facilitate drug/cargo delivery and mitigate off-site adverse effects [123].…”